Comparison of the Sensor-Augmented Pump System with the Advanced Hybrid Closed-Loop Delivery System: Quality of Life, Diabetes Distress, and Glycaemic Outcomes in a Real-Life Context

Background Type 1 diabetes mellitus (T1D) is a chronic disease that requires exogenous insulin administration and intensive management to prevent any complications. Recent innovations in T1D management technologies include the Advanced Hybrid Closed-Loop delivery system (AHCL). The pioneer AHCL system provides automated basal and automated bolus corrections when neededObjectives This study aimed to compare the Advanced Hybrid Closed-Loop (AHCL) system and the Sensor-Augmented Pump (SAP) with Predictive Low Glucose Management (PLGM) system, in relation to glycaemic outcomes, general and diabetes-related Quality of Life (QoL), and diabetes distress.Methods General and diabetes-related QoL were assessed with the Diabetes Quality of Life Brief Clinical Inventory (DQOL-BCI) and the World Health Organization Quality of Life-BREF (WHOQOL-BREF), respectively. Diabetes distress was assessed with the Diabetes Distress Scale for Type 1 diabetes (T1-DDS).Results Eighty-nine T1D adults participated in the study, mostly females (65.2%), with a mean age of 39.8 (& PLUSMN; 11.5 years). They had on average 23 years of diabetes (& PLUSMN; 10.7) and they were on continuous subcutaneous insulin infusion therapy. Significant differences favoring the AHCL over the SAP + PLGM system were demonstrated by lower mean glucose levels, less time above range, lower scores on DQOL-BCI, T1-DDS, and higher scores on WHOQOL-BREF. Finally, the linear regression models revealed the association of time in range in most of the above aspects.Conclusion This study highlighted the advantages of the AHCL system over the SAP + PLGM system in the real-world setting in relation to general and diabetes-related QoL, diabetes distress, and glycaemic outcomes.

Automated summary

This study compared the Advanced Hybrid Closed-Loop (AHCL) system with the Sensor-Augmented Pump (SAP) with Predictive Low Glucose Management (PLGM) system in terms of glycaemic outcomes, general and diabetes-related Quality of Life (QoL), and diabetes distress. The findings demonstrated that the AHCL system had significant advantages over the SAP + PLGM system in terms of mean glucose levels, time above range, QoL, and diabetes distress. Linear regression models also revealed the association between time in range and these aspects.